Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

BNBX - BNB Plus Corp. Latest News | Finranks

Home

BNBX

B

BNB Plus Corp. (BNBX)

NCM – Real Time Price. Currency in USD

0.69

-0.01 (-0.73%)

At close: Mar 27, 2026, 4:00 PM EDT

0.68

-0.01 (-0.94%)

After-hours: Mar 27, 2026, 7:51 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has been granted a European patent by the European Patent Office (EPO) related to European Patent Application No.: 21882234.4 (EP4232569A1) entitled "Compositions and Methods for RNA Synthesis." The European patent grant follows a U.S. patent grant in 2024 and covers the composition of LineaRx's chemically modified RNA polymerase (.

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company") today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has received two new orders for LineaDNA from well-established developers of genetic medicines. Production and shipment of both orders is expected to be completed prior to June 2026. "We're pleased to receive these new orders from leading genetic medicine companies,” said Clay Shorrock, President and CEO of BNBX. “We believe our con.

BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director

BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced the appointment of James Haft as an Independent Director and member of the Board's Nominating Committee, effective as of February 2, 2026. Mr. Haft is a recognized pioneer in digital asset investments and decentralized finance, bringing more than 35 years of experience spanning blockchain infrastructure, emerging markets, and traditional finance. Mr. Haft has served as a managing director at Bear.

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital Asset Virtual Investor Conference hosted by Virtual InvestorConferences.com, on January 27th, 2026 at 1:00PM EST. DATE: January 27th, 2026 TIME: 1:00PM EST Register here Mr.

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital Asset Virtual Investor Conference hosted by Virtual InvestorConferences.com, on January 27th, 2026 at 1:00PM EST. DATE: January 27th, 2026 TIME: 1:00PM EST Register here Mr. Horsman and Mr. Kruger will be available for 1x1 meetings on January 27-29. Participants may schedule.

BNB Plus Corp. (BNBX) Receives $1.2M Accelerated LineaDNA™ Order

BNB Plus Corp. (BNBX) Receives $1.2M Accelerated LineaDNA™ Order

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has received a $1.2M USD order for LineaDNA, representing the largest LineaDNA order in Company history. The order is an acceleration of an existing customer's annual purchasing cadence, consolidating what was originally planned as a two-year order cycle into an accelerated delivery schedule expected to be completed by May 2026. The order was placed by a global manufacturer of in vitro di.

BNB Plus Corp. (BNBX) Announces Largest Ever Shipment of LineaDNATM

BNB Plus Corp. (BNBX) Announces Largest Ever Shipment of LineaDNATM

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has successfully manufactured and shipped the largest single LineaDNA order in Company history, valued at over $390,000 USD. The approximately 5-gram shipment, manufactured by the Company's LineaRx, Inc. subsidiary, was delivered under the Company's previously announced supply agreement for the bulk manufacture of LineaDNA used as a functional component of a cancer diagnostic test (“the “.

Videos

No Data

There is no data to display

Press releases

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has been granted a European patent by the European Patent Office (EPO) related to European Patent Application No.: 21882234.4 (EP4232569A1) entitled "Compositions and Methods for RNA Synthesis." The European patent grant follows a U.S. patent grant in 2024 and covers the composition of LineaRx's chemically modified RNA polymerase (.

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company") today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has received two new orders for LineaDNA from well-established developers of genetic medicines. Production and shipment of both orders is expected to be completed prior to June 2026. "We're pleased to receive these new orders from leading genetic medicine companies,” said Clay Shorrock, President and CEO of BNBX. “We believe our con.

BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director

BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced the appointment of James Haft as an Independent Director and member of the Board's Nominating Committee, effective as of February 2, 2026. Mr. Haft is a recognized pioneer in digital asset investments and decentralized finance, bringing more than 35 years of experience spanning blockchain infrastructure, emerging markets, and traditional finance. Mr. Haft has served as a managing director at Bear.

BNB Plus Corp. (BNBX) Receives $1.2M Accelerated LineaDNA™ Order

BNB Plus Corp. (BNBX) Receives $1.2M Accelerated LineaDNA™ Order

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has received a $1.2M USD order for LineaDNA, representing the largest LineaDNA order in Company history. The order is an acceleration of an existing customer's annual purchasing cadence, consolidating what was originally planned as a two-year order cycle into an accelerated delivery schedule expected to be completed by May 2026. The order was placed by a global manufacturer of in vitro di.